||Penciclovir is a Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor. In HSV infected cells, penciclovir is phosphorylated by viral thymidine kinase and subsequently converted b
||Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat
||PSI-6206 (RO2433) is a selective HCV RNA polymerase inhibitor.
||Maribavir is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of the viral UL97 kinase, whic
||Paritaprevir is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A),
||Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in
||Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) non-structural protein 5B (NS5B), an RNA-dependent RNA polymerase, with potential activity against HCV. Upon
||HZ-1157 is a hepatitis C virus (HCV) inhibitor with inhibitory activities toward HCV NS3/4A protease.
||Ledipasvir (GS5885) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
||Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV).
||Telaprevir (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 μM).
||Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
||Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in
||Sofosbuvir is a uridine monophosphate analog inhibitor of hepatitis C virus (HCV) polymerase NS5B that is used as an antiviral agent in the treatment of chronic hepatitis C.
||VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM.
||Asunaprevir is an effective hepatitis C virus (HCV) NS3 protease inhibitor.
||Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.
||Simeprevir is a potent HCV NS3/4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.
||Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assa
||ABT-530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6.
||Glecaprevir is an HCV NS3/4A protease inhibitor, (IC50s: 3.5-11.3 nM).
||Letermovir (AIC246) is a novel anti-CMV compound (EC50: about 5 nM in fibroblast cells). It targets the pUL56 subunit of the viral terminase complex.
||4-Phenoxybenzylamine inhibits the function of the NS3 protein by stabilizing an inactive conformation with an IC50 of about 500 μM against HCV NS3/4a .
||Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5
||NM107 is a ribonucleoside with broad-spectrum antiviral activity, is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, NM 107 in the wild-type replicon cells
||Tomeglovir is a potent anti-CMV agent, inhibiting the processing of viral DNA-concatemers (IC50s: 0.34/0.039 μM for HCMV and MCMV).
||Nesbuvir (HCV-796) is a nonnucleoside inhibitor of the HCV nonstructural protein 5B (NS5B) polymerase.
||VCH-916 is a new nonnucleoside inhibitor of HCV NS5B polymerase.
||R-1479 is an HCV replication inhibitor in the HCV subgenomic replicon system (IC50: 1.28 μM).
||MK-5172 is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Ki of 0.01 nM (gt1a), 0.08 nM (gt2a), 0.90 n
||gamma-Fagarine possesses moderate levels of anti-HCV activities with IC50 values being 20.4 ± 0.4 ug/ml, respectively. It has sister chromatid exchanges (SCEs)-inducing activity
||Glycyrin, one of the main PPAR-gamma ligands of licorice, can significantly decrease the blood glucose levels of genetically diabetic KK-A(y) mice.
||Platycodin D3 is a NF-κB inhibitor, it could as expectorants in diverse inflammatory pulmonary diseases, it can regulate the production and secretion of airway mucin; it can signi
||Syrosingopine has selective depleting effect on brain amines is potentiated by combined treatment with disulfiram or fusaric acid, a dopamine beta-hydroxylase inhibitor.
||Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor(EC50 range of 0.1-0.5 μM)
||2',5-Difluoro-2'-deoxycytidine has potent anti-HCV activity and toxicity to rRNA.
||ACH-806 is an NS4A antagonist. It can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM.
||BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication and it is also highly selective against other serine/cysteine proteases. BI-1230 shows
||Sofosbuvir impurity A
||Sofosbuvir impurity A is an diastereoisomer of Sofosbuvir. Sofosbuvir is anHCV RNA replication inhibitor ,with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity F
||Sofosbuvir impurity F is a diastereoisomer of Sofosbuvir. Sofosbuvir is anHCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity G
||Sofosbuvir impurity G is a diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity H
||Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is a diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replicatio
||Sofosbuvir impurity I
||Sofosbuvir impurity I is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity J
||Sofosbuvir impurity J is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity K
||Sofosbuvir impurity K is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity L
||Sofosbuvir impurity L is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity M
||Sofosbuvir impurity M is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Sofosbuvir impurity N
||Sofosbuvir impurity N is an diastereoisomer of Sofosbuvir.Sofosbuvir is an HCV RNA replication inhibitor, with potent anti-hepatitis C virus activity.
||Valopicitabine is an effective prodrug of the effective anti-HCV drug 2'-C-methylcytidine and can be used as a promising antiviral drug for the study of chronic HCV infection.
||PSI-352938 is an inhibitor of hepatitis C virus nucleotide.
||RO-9187 is an effective HCV virus replication inhibitor(IC50: 171 nM).
||MK-0608 is an orally bioavailable HCV replication inhibitor in vitro(EC50 = 0.3 μM and EC90=1.3 μM in the subgenomic-replicon assay).
||Arborinine shows mild in vitro antibacterial activity, it possesses moderate levels of anti-hepatitis C virus(HCV) activities with the IC50 values being 6.4 ± 0.7 ug/ml. Arborinin
||Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistan
||Ladanein is a phytochemicals inhibitor that is known to disrupt the interactions of core and other hepatitis C virus (HCV) proteins.Ladanein possesses free radicals DPPH and ABTS +
||Sulochrin shows antifungal and antibacterial activities, it can inhibit hepatitis C virus (HCV) infection in a dose-dependent manner without any apparent cytotoxicity up to 50 uM.
||Xanthohumol has anti-hepatitis C virus, anti-carcinogenic, free radical-scavenging, and anti-inflammatory activities, it can inhibit HIV-1 induced cytopathic effects, the productio
||Inarigivir soproxil is an agonist of innate immunity. It also displays effective antiviral activity against resistant hepatitis C virus (HCV) variants (EC50s of 2.2 and 1.0 μM for
||Tegobuvir is a specific and covalent HCV NS5B polymerase inhibitor.
||BLT-1 is a scavenger receptor BI (SR-BI)inhibitor.
||Lycorine (hydrochloride) is VE-cadherin inhibitor,and has IC50 of 1.2μM in Hey1B cell.It is an HCV inhibitor with strong activity.
||Voxilaprevir is an inhibitor of hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease.
||Artemisinin is an ancient Chinese herbal therapy for malarial fevers which has been recently found to have potent activity against many forms of malarial organisms, including chlor
||Mecarbinate is arbidol hydrochloride's chemical intermediate.
||Peretinoin is an oral acyclic retinoid with a vitamin A-like structure that targets retinoid nuclear receptors such as RXR and RAR.